Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT™ in Recurrent Cutaneous SCC

/PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy...

Related Keywords

Jerusalem ,Israel General ,Israel ,United States ,Israeli ,Intratumoral Alpha Da ,Yaniv Sagie ,Itzhak Kelson ,Alpha Da ,Yona Keisari ,Breakthrough Device Designation Program ,Regulatory Affairs ,Drug Administration ,Nasdaq ,Alpha Tau Medical Ltd ,Company Investigational Device Exemption ,Exchange Commission ,Prnewswire Alpha Tau Medical Ltd ,Tel Aviv University ,Tau Medical ,Investigational Device Exemption ,Squamous Cell Carcinoma ,Prospective Multicenter ,Single Arm ,Open Label Clinical Study ,Intratumoral Alpha ,Recurrent Cutaneous Squamous Cell ,Alpha Tau ,Alpha Tau Chief Medical Officer ,Device Designation ,Diffusing Alpha Emitters Radiation Therapy ,Alpha Tau Medical ,Tel Aviv ,Private Securities Litigation Reform Act ,Annual Report ,United States Securities ,